Document is current

Article History

Received: 19 July 2023

Accepted: 1 December 2023

First Online: 11 December 2023

Declarations

:

: Not applicable.

: P.H. has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and New South Wales Institute of Psychiatry and royalties from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, and she has received research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration in Australia (2019–) and an Editor in Chief of this journal. In July 2017, she provided a commissioned report for Takeda (formerly Shire) Pharmaceuticals on lisdexamfetamine and binge eating disorder, is a consultant to Takeda, and in 2018–2020 received honoraria for education of Psychiatrists. S.T. receives royalties from Taylor and Francis, Hogrefe and Huber and McGraw Hill for published book chapters. He has received honoraria from Shire/ Takeda Group of Companies for chairing the Australian Clinical Advisory Board for Binge Eating Disorder, public speaking engagements, commissioned reports as well as investigator- initiated research grants. He is an Editor in Chief of this journal, an inaugural committee member of the National Eating Disorders Collaboration, a Member of the Technical Advisory Group (TAG) on Eating Disorders (Commonwealth of Australia) and a member of the governing council of the Australian Eating Disorders Research and Translation Centre. DLG receives royalties from Guilford Press and Routledge, is Co-Director of the Training Institute for Child and Adolescent Eating Disorders, LLC, and is a member of Equip Health Clinical Advisory Board. The other authors have no conflicts of interest to disclose.